Abstract
Prevention of oxidative stress and inflammation in chronic kidney disease patients (CKD) on dialysis may reduce dialysis-associated complications. Administration of powerful antioxidants may improve the consequences of peritoneal dialysis (PD) and hemodialysis (HD). This narrative review aimed to show the potential therapeutic effects of melatonin (MLT) on the consequences of CKD patients receiving HD or PD. The results of preclinical and clinical studies have proven that CKD and dialysis are accompanied by reduced endogenous MLT levels and related complications such as sleep disorders. Enhanced oxidative stress, inflammation, cellular damages, and renal fibrosis, along with dysregulation of the renin-angiotensin system (RAS), have been observed in CKD and patients on dialysis. Results of studies have revealed that the restoration of MLT via the exogenous source may regulate oxidative stress, inflammation, and RAS functions, inhibit fibrosis, and improve complications in patients with long-term dialysis patients. In summary, treatment of patients with CKD and dialysis with exogenous MLT is suggested as a practical approach in reducing the outcomes and improving the quality of life in patients via antioxidant, anti-inflammatory, and anti-fibrotic signaling pathways. Therefore, this hormone can be considered in clinical practice to manage dialysis-related complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
No datasets were generated or analyzed during the current study.
References
Agabiti-Rosei C et al (2017) Effect of long-term treatment with melatonin on vascular markers of oxidative stress/inflammation and on the anticontractile activity of perivascular fat in aging mice. Hypertens Res 40:41–50
Andreoli MC et al (2007) Impact of dialyzer membrane on apoptosis and function of polymorphonuclear cells and cytokine synthesis by peripheral blood mononuclear cells in hemodialysis patients. Artif Organs 31:887–892. https://doi.org/10.1111/j.1525-1594.2007.00485.x
Azizi M et al (2018) Therapeutic effect of perinatal exogenous melatonin on behavioral and histopathological changes and antioxidative enzymes in neonate mouse model of cortical malformation. Int J Dev Neurosci 68:1–9
Azizi M, Pasbakhsh P, Sadr M, Mokhtari T, Pourabdollah M, Nadji SA, Ragerdi Kashani I (2020) Effects of exogenous melatonin on MAM induced lung injury and lung development in mice offspring. Tanaffos 19:66–73
Baragetti I, El Essawy B, Fiorina P (2017) Targeting immunity in end-stage renal disease. Am J Nephrol 45:310–319. https://doi.org/10.1159/000458768
Benigni A, Cassis P, Remuzzi G (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2(7):247–257. https://doi.org/10.1002/emmm.201000080
Bicer A, Guclu B, Ozkan A, Kurtkaya O, Koc DY, Necmettin Pamir M, Kilic T (2010) Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J Clin Neurosci 17:232–236. https://doi.org/10.1016/j.jocn.2009.06.008
Biernacka A, Dobaczewski M, Frangogiannis NG (2011) TGF-β Signaling in Fibrosis Growth Factors 29:196–202. https://doi.org/10.3109/08977194.2011.595714
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative Stress and Antioxidant Defense World Allergy Organ J 5:9–19. https://doi.org/10.1097/WOX.0b013e3182439613
Borawski J (2006) Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis 47(1):37–41. https://doi.org/10.1053/j.ajkd.2005.10.001
Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease Kidney Int Suppl:S4–9 doi:https://doi.org/10.1038/ki.2008.516
Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC (2019) An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med 49:2307–2319. https://doi.org/10.1017/s0033291719001995
Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM (2013) Melatonin: buffering the immune system. Int J Mol Sci 14(4):8638–8683. https://doi.org/10.3390/ijms14048638
Cho Y, Johnson DW (2014) Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 64(2):278–289
Cobo G, Lindholm B, Stenvinkel P (2018) Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 33(suppl_3):iii35–iii40. https://doi.org/10.1093/ndt/gfy175
Collins AJ et al (2003) Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 42(1 Suppl 1):A5–7-s1–230
Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O (2000) Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 11:717–728
de Lima SMA et al (2013) Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis. Clinica Chimica Acta 5(421):46–50. https://doi.org/10.1016/j.cca.2013.02.027
Edalat-Nejad M, Haqhverdi F, Hossein-Tabar T, Ahmadian M (2013) Melatonin improves sleep quality in hemodialysis patients Indian. J Nephrol 23:264–269. https://doi.org/10.4103/0971-4065.114488
Elshahat S, Cockwell P, Maxwell AP, Griffin M, O’Brien T, O’Neill C (2020) The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS ONE 15:e0230512. https://doi.org/10.1371/journal.pone.0230512
Erşahin M et al (2009) Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res 47(1):97–106
Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8:228–242. https://doi.org/10.2174/157015910792246155
Fonseca NT et al (2016) A systematic review of sleep disorders in patients with chronic kidney disease undergoing hemodialysis. J Phys Ther Sci 28:2164–2170. https://doi.org/10.1589/jpts.28.2164
Fraser SD, Blakeman T (2016) Chronic Kidney Disease: Identification and Management in Primary Care. Pragmat Obs Res 7:21–32. https://doi.org/10.2147/por.S97310
Fujii H, Goto S, Fukagawa M (2018) Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins (Basel) 10(5):202. https://doi.org/10.3390/toxins10050202
Gorostidi M et al (2014) Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrologia 34(3):302–316. https://doi.org/10.3265/Nefrologia.pre2014.Feb.12464
Gul A, Aoun N, Trayner EM Jr (2006) Why do patients sleep on dialysis? Semin Dial 19(2):152–157. https://doi.org/10.1111/j.1525-139X.2006.00142.x
Hacışevki A, Baba B (2018) An overview of melatonin as an antioxidant molecule: a biochemical approach Melatonin molecular biology, clinical and pharmaceutical approaches:59–85
Hayati F, Mousavi SSB, Movahed SMM, Bushehri MM (2017) Pulmonary hypertension among patients undergoing hemodialysis Journal of Renal. Inj Prev 6:122
Hedayatpour A et al (2018) Co-administration of progesterone and melatonin attenuates ischemia-induced hippocampal damage in rats. J Mol Neurosci 66:251–260
Herrera J, Nava M, Romero F, Rodríguez-Iturbe B (2001) Melatonin Prevents Oxidative Stress Resulting from Iron and Erythropoietin Administration. Am J Kidney Dis 37(4):750–757. https://doi.org/10.1016/s0272-6386(01)80124-4
Hewitson TD (2012) Fibrosis in the kidney: is a problem shared a problem halved? Fibrogenesis & Tissue Repair 5:S14. https://doi.org/10.1186/1755-1536-5-S1-S14
Himmelfarb J (2009) Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 22(6):636–643. https://doi.org/10.1111/j.1525-139X.2009.00659.x
Holley JL, Nespor S, Rault R (1992a) A comparison of reported sleep disorders in patients on chronic hemodialysis and continuous peritoneal dialysis. Am J Kidney Dis 19:156–161
Holley JL, Nespor S, Rault R (1992b) A Comparison of Reported Sleep Disorders in Patients on Chronic Hemodialysis and Continuous Peritoneal Dialysis. Am J Kidney 19(9):156–161. https://doi.org/10.1016/s0272-6386(12)70125-7
Hosseinzadeh A, Javad-Moosavi SA, Reiter RJ, Hemati K, Ghaznavi H, Mehrzadi S (2018) Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin. Life Sci 15(201):17–29
Hrenak J, Paulis L, Repova K, Aziriova S, Nagtegaal EJ, Reiter RJ, Simko F (2015) Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies. Curr Phar Des 21(7):936–949
Hu W et al (2016) Melatonin: the dawning of a treatment for fibrosis? J Pineal Res 60(2):121–131
Husain-Syed F, McCullough PA, Birk H-W, Renker M, Brocca A, Seeger W, Ronco C (2015) Cardio-pulmonary-renal interactions: a multidisciplinary approach. J Am Coll Cardiol 65(22):2433–2448. https://doi.org/10.1016/j.jacc.2015.04.024
Inker LA et al (2016) Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68(3):392–401
Inrig JK (2010) Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis. Am J Kidney Dis 55(3):580–589
Ishigaki S et al (2016) Impaired endogenous nighttime melatonin secretion relates to intrarenal renin–angiotensin system activation and renal damage in patients with chronic kidney disease. Clin Exp Nephrol 20(6):878–884
Ishigaki S et al (2018) Melatonin ameliorates intrarenal renin-angiotensin system in a 5/6 nephrectomy rat model. Clin Exp Nephrol 22(3):539–549. https://doi.org/10.1007/s10157-017-1505-7
Jofré R, Rodriguez-Benitez P, López-Gómez JM, Pérez-Garcia R (2006) Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 17(12 Suppl 3):S274-280. https://doi.org/10.1681/asn.2006080926
Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J (2005a) Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuroendocrinol Lett 26(6):653–656
Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J (2005b) Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuro Endocrinol Lett 26(6):653–656
Kim JW, Jo J, Kim J-Y, Choe M, Leem J, Park J-H (2019) Melatonin Attenuates Cisplatin-Induced Acute Kidney Injury through Dual Suppression of Apoptosis and Necroptosis. Biology 8(3):64
Kobori H, Nangaku M, Navar LG, Nishiyama A (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59(3):251–287
Kobori H, Urushihara M (2013) Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease Pflügers Archiv-European. J Physiol 465(1):3–12
Koch BC, Van der Putten K, Van Someren EJ, Wielders JP, Ter Wee PM, Nagtegaal JE, Gaillard CA (2010) Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrol Dial Transplant 25(2):513–519
Koch BCP, Nagtegaal JE, Hagen EC, van der Westerlaken MML, Boringa JBS, Kerkhof GA, Ter Wee PM (2009) The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients: a randomized, placebo-controlled, cross-over study (EMSCAP study). Br J Clin Pharmacol 67(1):68–75. https://doi.org/10.1111/j.1365-2125.2008.03320.x
Krueger JM (2008) The role of cytokines in sleep regulation. Curr Pharm Des 14(32):3408–3416. https://doi.org/10.2174/138161208786549281
Kucuktulu E (2012) Protective effect of melatonin against radiation induced nephrotoxicity in rats. Asian Pa J Cancer Prev 13(8):4101–4105
Lee SY, Kim SI, Choi ME (2015) Therapeutic targets for treating fibrotic kidney diseases. Transl Res 165(4):512–530. https://doi.org/10.1016/j.trsl.2014.07.010
Leibowitz A, Volkov A, Voloshin K, Shemesh C, Barshack I, Grossman E (2016) Melatonin prevents kidney injury in a high salt diet-induced hypertension model by decreasing oxidative stress. J Pineal Res 60:48–54
Letizia C et al (1995) Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis. Int Urol Nephrol 27(4):465–470
Li N, Wang Z, Gao F, Lei Y, Li Z (2020) Melatonin ameliorates renal fibroblast‐myofibroblast transdifferentiation and renal fibrosis through miR‐21‐5p regulation. J Cell Mol Med 24(10):5615–5628
Liakopoulos V, Roumeliotis S, Bozikas A, Eleftheriadis T, Dounousi E (2019a) Antioxidant supplementation in renal replacement therapy patients: is there evidence? Oxidative medicine and cellular longevity 2019
Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR (2017) Oxidative Stress in Hemodialysis Patients: a Review of the Literature Oxid Med Cell Longev 2017:3081856. https://doi.org/10.1155/2017/3081856
Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR (2017b) Oxidative stress in hemodialysis patients: a review of the literature Oxidative medicine and cellular longevity 2017
Liakopoulos V, Roumeliotis S, Gorny X, Eleftheriadis T, Mertens PR (2017) Oxidative Stress in Patients Undergoing Peritoneal Dialysis: a Current Review of the Literature Oxid. Med Cell Longev 2017:3494867–3494867. https://doi.org/10.1155/2017/3494867
Liakopoulos V, Roumeliotis S, Zarogiannis S, Eleftheriadis T, Mertens PR (2019b) Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial 32(1):58–71. https://doi.org/10.1111/sdi.12745
Liu Z, Ren Z, Zhang J, Chuang C-C, Kandaswamy E, Zhou T, Zuo L (2018) Role of ROS and Nutritional Antioxidants in Human Diseases. Front Physiol 9:477–477. https://doi.org/10.3389/fphys.2018.00477
Liyanage T et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385:1975–1982. https://doi.org/10.1016/s0140-6736(14)61601-9
Loboda A, Sobczak M, Jozkowicz A, Dulak J (2016) TGF-β1/Smads and miR-21 in renal fibrosis and inflammation Mediators of inflammation 2016
Lopez-Giacoman S, Madero M (2015) Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 4(1):57–73. https://doi.org/10.5527/wjn.v4.i1.57
Maher ER, Wickens DG, Griffin JF, Kyle P, Curtis JR, Dormandy TL (1987) Increased free-radical activity during haemodialysis? Nephrol Dial Transplant 2:169–171
Malik U, Raizada V (2015) Some aspects of the renin-angiotensin-system in hemodialysis patients. Kidney Blood Press Res 40:614–622
Malliara M (2007) The management of hypertension in hemodialysis and CAPD patients. Hippokratia 11:171–174
Maraj M et al. (2018) Malnutrition, inflammation, atherosclerosis syndrome (MIA) and diet recommendations among end-stage renal disease patients treated with maintenance hemodialysis Nutrients 10 doi:https://doi.org/10.3390/nu10010069
Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J (2001) Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 12(10):2029–2039
Maung SC, El Sara A, Chapman C, Cohen D, Cukor D (2016) Sleep disorders and chronic kidney disease World. J Nephrol 5:224–232. https://doi.org/10.5527/wjn.v5.i3.224
Meng X-M, Nikolic-Paterson DJ, Lan HY (2014) Inflammatory processes in renal fibrosis. Nat Rev Nephrol 10:493
Miyata T, Kurokawa K (2000) Van Ypersele De Strihou C. Advanced Glycation and Lipoxidation End Products: Role of Reactive Carbonyl Compounds Generated during Carbohydrate and Lipid Metabolism J Am Soc Nephrol 11:1744–1752
Mokhtari T, Faghir Ghanesefat H, Hassanzadeh G, Moayeri A, Haeri SMJ, Rezaee Kanavee A, Mousavi Movahed SM (2017) Effects of Flaxseed Oil Supplementation on Renal Dysfunction Due to Ischemia/reperfusion in Rat Journal of Basic Research in Medical Sciences 4:22–29. https://doi.org/10.18869/acadpub.jbrms.4.1.22
Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP (2005) Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 9:37–46. https://doi.org/10.1111/j.1492-7535.2005.01116.x
Movahed SMM, Mousavi SSB, Faramarzi M (2017) Secondary hyperparathyroidism among end-stage renal disease patients in Beharlou hospital. Tehran Province, Iran Journal of Parathyroid Disease 6:64–67
Naseri S, Moghahi SMHN, Mokhtari T, Roghani M, Shirazi AR, Malek F, Rastegar T (2017) Radio-protective effects of melatonin on subventricular zone in irradiated rat: decrease in apoptosis and upregulation of Nestin. J Mol Neurosci 63:198–205
Nessim SJ, Perl J, Bargman JM (2010) The renin–angiotensin–aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int 78:23–28. https://doi.org/10.1038/ki.2010.90
Nicholl DD, Hanly PJ, Poulin MJ, HandleyHemmelgarn GBBR, Sola DY, Ahmed SB (2014) Evaluation of continuous positive airway pressure therapy on renin–angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med 190(5):572–580
Ogunro PS, Olujombo FA, Ajala MO, Oshodi TT (2014) The effect of a membrane dialyzer during hemodialysis on the antioxidant status and lipid peroxidation of patients with end-stage renal disease. Saudi J Kidney Dis Transpl 25:1186–1193. https://doi.org/10.4103/1319-2442.144251
Ohashi N, Ishigaki S, Isobe S (2019) The pivotal role of melatonin in ameliorating chronic kidney disease by suppression of the renin–angiotensin system in the kidney. Hypertens Res 42(6):761–768
Ohashi N et al (2017) Intrarenal renin-angiotensin system activity is augmented after initiation of dialysis. Hypertens Res 40:364–370. https://doi.org/10.1038/hr.2016.143
Ostadmohammadi V et al (2020) The effects of melatonin supplementation on parameters of mental health, glycemic control, markers of cardiometabolic risk, and oxidative stress in diabetic hemodialysis patients: a randomized, double-blind, placebo-controlled trial. J Renal Nutr 30(3):242–250
Ozbek E, Ilbey YO, Ozbek M, Simsek A, Cekmen M, Somay A (2009) Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS. MAPK, and NF-kB Expression J Endourol 23:1165–1173. https://doi.org/10.1089/end.2009.0035
Pardo A, Cabrera S, Maldonado M, Selman M (2016) Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res 17:23–23. https://doi.org/10.1186/s12931-016-0343-6
Parker KP (2003) Sleep disturbances in dialysis patients. Sleep Med Rev 7:131–143. https://doi.org/10.1053/smrv.2001.0240
Parker KP, Bliwise DL, Rye DB (2000) Hemodialysis disrupts basic sleep regulatory mechanisms: building hypotheses. Nurs Res 49:327–332. https://doi.org/10.1097/00006199-200011000-00006
Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O (2006) Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26(1):53–63
Pecoits-Filho R, Lindholm B, Stenvinkel P (2002) The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. Nephrol Dial Transplant 17(Suppl 11):28–31. https://doi.org/10.1093/ndt/17.suppl_11.28
Peng Z, Zhang W, Qiao J, He B (2018) Melatonin attenuates airway inflammation via SIRT1 dependent inhibition of NLRP3 inflammasome and IL-1β in rats with COPD International immunopharmacology 62:23–28
Phaniendra A, Jestadi DB, Periyasamy L (2015) Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 30(1):11–26. https://doi.org/10.1007/s12291-014-0446-0
Qin J, Peng Z-Z, Li Q, Wen R, Tao L-J (2018) Renal fibrosis and mitochondrial damage. Chin Med J (engl) 131:2769–2772. https://doi.org/10.4103/0366-6999.245272
Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B (2008) Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 294(2):F336-344. https://doi.org/10.1152/ajprenal.00500.2007
Rahman A, Hasan AU, Nishiyama A, Kobori H (2018) Altered circadian timing system-mediated non-dipping pattern of blood pressure and associated cardiovascular disorders in metabolic and kidney diseases. Int J Mol Sci 19:400
Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S (2019) Inflammation and ixidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci 21(1):263. https://doi.org/10.3390/ijms21010263
Raza Z, Naureen Z (2020) Melatonin Ameliorates the Drug Induced Nephrotoxicity: Molecular Insights. Nefrología 40(1):12–25. https://doi.org/10.1016/j.nefroe.2020.03.001
Remacle J, Raes M, Toussaint O, Renard P, Rao G (1995) Low levels of reactive oxygen species as modulators of cell function. Mutat Res 316:103–122. https://doi.org/10.1016/0921-8734(95)90004-7
Ren H, Sun R, Wang J (2018) Relationship of melatonin level, oxidative stress and inflammatory status with osteoporosis in maintenance hemodialysis of chronic renal failure. Exp Ther Med 15(6):5183–5188
Roumelioti M-E et al (2016) Objective and Subjective Sleep Disorders in Automated Peritoneal Dialysis. Can J Kidney Health Dis 3:6–6. https://doi.org/10.1186/s40697-016-0093-x
Roumeliotis S, Eleftheriadis T, Liakopoulos V (2019) Is oxidative stress an issue in peritoneal dialysis? Semin Dial 32:463–466. https://doi.org/10.1111/sdi.12818
Russcher M et al (2015) The effects of kidney transplantation on sleep, melatonin, circadian rhythm and quality of life in kidney transplant recipients and living donors. Nephron 129(1):6–15. https://doi.org/10.1159/000369308
Sakai N, Chun J, Duffield JS, Wada T, Luster AD, Tager AM (2013) LPA1‐induced cytoskeleton reorganization drives fibrosis through CTGF‐dependent fibroblast proliferation. FASEB J 27(5):1830–1846
Sardo FL, Muti P, Blandino G, Strano S (2017) Melatonin and Hippo pathway: is there existing cross-talk? Int J Mol Sci 18:1913
Sela S et al (2005) Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16:2431–2438. https://doi.org/10.1681/asn.2004110929
Simko F et al (2018) Effect of melatonin on the renin-angiotensin-aldosterone system in L-NAME-induced hypertension. Molecules 23(2):265
Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT (2012) Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 351:152–166. https://doi.org/10.1016/j.mce.2012.01.004
Srinivasan V, Spence DW, Pandi-Perumal SR, Brown GM, Cardinali DP (2011) Melatonin in Mitochondrial Dysfunction and Related Disorders International Journal of Alzheimer’s Disease 2011:326320. https://doi.org/10.4061/2011/326320
Tan D-X, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ (2015) Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules 20:18886–18906. https://doi.org/10.3390/molecules201018886
Tan D-X et al (2014) Fundamental issues related to the origin of melatonin and melatonin isomers during evolution: relation to their biological functions. Int J Mol Sci 15:15858–15890. https://doi.org/10.3390/ijms150915858
Tikellis C, Thomas M (2012) Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease International journal of peptides 2012
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C (2017) Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol 15(3):434–443
Varan HI, Dursun B, Dursun E, Ozben T, Suleymanlar G (2010) Acute Effects of Hemodialysis on Oxidative Stress Parameters in Chronic Uremic Patients: Comparison of Two Dialysis Membranes. Int J Nephrol Renovasc Dis 3:39–45. https://doi.org/10.2147/ijnrd.s6598
Vaziri ND, Oveisi F, Reyes GA, Jhou X-J (1996) Dysregulation of melatonin metabolism in chronic renal insufficiency: role of erythropoietin-deficiency anemia. Kidney Int 50:653–656
Walker S, Fine A, Kryger MH (1995) Sleep complaints are common in a dialysis unit. Am J Kidney Dis 26:751–756
Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD (1995) Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 47(1):282–293. https://doi.org/10.1038/ki.1995.36
Wong MKS (2016) Chapter 29 - Renin-angiotensin system. In: Takei Y, Ando H, Tsutsui K (eds) Handbook of hormones. Academic Press, San Diego, pp 253-e229–253. doi: https://doi.org/10.1016/B978-0-12-801028-0.00029-5
Xie Z et al (2017) A review of sleep disorders and melatonin. Neurol Res 39:559–565. https://doi.org/10.1080/01616412.2017.1315864
Xu H et al (2015) Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int 35:206–215. https://doi.org/10.3747/pdi.2013.00259
Yoon YM, Go G, Yun CW, Lim JH, Lee JH, Lee SH (2020) Melatonin suppresses renal cortical fibrosis by inhibiting cytoskeleton reorganization and mitochondrial dysfunction through regulation of miR-4516. Int J Mol Sci 21(15):5323
Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55:4044–4049
Zhao L, Hu C, Zhang P, Jiang H, Chen J (2020) Melatonin preconditioning is an effective strategy for mesenchymal stem cell-based therapy for kidney disease. J Cell Mol Med 24:25–33. https://doi.org/10.1111/jcmm.14769
Zhou D et al (2017) Tubule-derived Wnts are required for fibroblast activation and kidney fibrosis. J Am Soc Nephrol 28:2322–2336. https://doi.org/10.1681/asn.2016080902
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648–658. https://doi.org/10.1046/j.1523-1755.1999.00273.x
Author information
Authors and Affiliations
Contributions
SMMM contributed to the design, searching the databases, and writing of the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
N/A
Consent for publication
N/A
Competing interests
The author declares no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Movahhed, S.M.M. Possible benefits of exogenous melatonin for individuals on dialysis: a narrative review on potential mechanisms and clinical implications. Naunyn-Schmiedeberg's Arch Pharmacol 394, 1599–1611 (2021). https://doi.org/10.1007/s00210-021-02099-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-021-02099-x